Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4] Ipamorelin significantly increases plasma growth hormone (GH).[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.[3] Ipamorelin Peptide is under active investigation in a number of cell culture and animal models

Discussion Our data suggest that in the first quarter of 2025, 4.9 million adults in Great Britain nearly one in ten either had recently used medication to support weight loss or were interested in doing so in the near future
Skin penetration depends on formulation, concentration, and application technique
Many clients report: Reduced cravings and food noise Improved energy and clarity Natural preference for balanced meals and hydration Weve also seen semaglutide help quite constant hunger signals, which allows clients to make more intentional choices, without feeling restricted or deprived
Lower blood pressure during weight loss and fluid shifts from nausea, vomiting, or poor intake can trigger reflex tachycardia
A few years later, scientists from the pharma company Amgen also raised doubts, claiming Sinclairs findings were erroneous